The analytical specificity and sensitivity, intra- and inter-assay repeatability and diagnostic characteristics of the kit were determined and compared with virus isolation, which is the gold standard.
The precision of the therascreen IDH1/2 kit was determined using a protocol based on the CLSI EP05-A2 [ 25].
The sensitivity of each kit was determined as a minimum rate of CFU providing the positive result in the PCR assay.
Plasma concentrations of glucose (Sopachem, Ochten, the Netherlands), triglycerides (TG), cholesterol (Instruchemie, Delfzijl, the Netherlands), glycerol (Sigma-Aldrich, Houten, the Netherlands) and free fatty acids (Wako Chemicals, Neuss, Germany; HR(2) Kit) were determined following the manufacturers' instructions.
Dr. Hamedanizadeh explains that distribution of the kits is determined by the size of the affected population and the number of Rural Health Units in the area.
Finally, the activity of bound enzyme in all kits was determined with tetramethylbenzidine/hydrogen peroxide substrate.
The concentration of RNA isolated with RNeasy kits was determined by measuring the absorbance at 260 nm in a UV-spectrophotometer.
The kit cut-off used is determined by addition of 0.15 absorbance units to the measured absorption (450 nm) of the negative control.
Signaling induced by Epo/EpoR and SCF/Kit is determined by the temporal and spatial expression of their cognate receptors at the surface of responsive cells.
Serum PSA, IL-12 (Bender Med Systems, ELISA kits Vienna, Austria), and IL-10 (R&D systems ELISA kits) levels were determined using ELISA kits as per standard protocol of manufacturers.
The kit components were determined after the PCR amplification conditions were serially optimized.
